Level Four Advisory Services LLC purchased a new stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX) during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 99,075 shares of the biopharmaceutical company’s stock, valued at approximately $357,000.
Several other hedge funds and other institutional investors also recently made changes to their positions in the company. FMR LLC increased its stake in Celldex Therapeutics by 40.3% in the fourth quarter. FMR LLC now owns 19,327,111 shares of the biopharmaceutical company’s stock worth $68,418,000 after buying an additional 5,555,595 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Celldex Therapeutics by 16.4% in the first quarter. Vanguard Group Inc. now owns 9,066,763 shares of the biopharmaceutical company’s stock worth $32,731,000 after buying an additional 1,278,206 shares during the last quarter. Columbia Wanger Asset Management LLC increased its stake in shares of Celldex Therapeutics by 113.1% in the fourth quarter. Columbia Wanger Asset Management LLC now owns 6,195,855 shares of the biopharmaceutical company’s stock worth $21,933,000 after buying an additional 3,288,332 shares during the last quarter. State Street Corp increased its stake in shares of Celldex Therapeutics by 4.7% in the first quarter. State Street Corp now owns 4,525,051 shares of the biopharmaceutical company’s stock worth $16,341,000 after buying an additional 202,375 shares during the last quarter. Finally, Meditor Group Ltd acquired a new stake in shares of Celldex Therapeutics during the first quarter worth $14,966,000. Institutional investors own 64.66% of the company’s stock.
Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) remained flat at $2.32 during trading on Friday. 5,370,315 shares of the stock were exchanged. The stock’s 50-day moving average is $2.92 and its 200 day moving average is $3.36. Celldex Therapeutics, Inc. has a one year low of $2.20 and a one year high of $5.02. The firm’s market capitalization is $290.24 million.
Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings data on Tuesday, May 9th. The biopharmaceutical company reported ($0.28) EPS for the quarter, hitting the consensus estimate of ($0.28). Celldex Therapeutics had a negative net margin of 1,825.82% and a negative return on equity of 53.10%. The business had revenue of $1.53 million for the quarter, compared to analyst estimates of $0.57 million. Equities analysts predict that Celldex Therapeutics, Inc. will post ($1.11) EPS for the current year.
ILLEGAL ACTIVITY WARNING: “Level Four Advisory Services LLC Buys New Position in Celldex Therapeutics, Inc. (CLDX)” was first reported by WKRB News and is owned by of WKRB News. If you are reading this report on another publication, it was stolen and reposted in violation of US and international copyright & trademark laws. The original version of this report can be viewed at https://www.wkrb13.com/markets/2228704/level-four-advisory-services-llc-buys-new-position-in-celldex-therapeutics-inc-cldx.html.
A number of analysts have weighed in on CLDX shares. Aegis reiterated a “buy” rating on shares of Celldex Therapeutics in a report on Tuesday, March 21st. Jefferies Group LLC reiterated a “hold” rating and set a $3.50 price target (down from $4.00) on shares of Celldex Therapeutics in a report on Thursday, May 11th. ValuEngine downgraded Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, June 3rd. HC Wainwright reiterated a “buy” rating and set a $6.00 price target on shares of Celldex Therapeutics in a report on Wednesday, March 15th. Finally, Cowen and Company reiterated a “buy” rating on shares of Celldex Therapeutics in a report on Tuesday, June 6th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the company’s stock. Celldex Therapeutics has a consensus rating of “Buy” and a consensus price target of $6.86.
About Celldex Therapeutics
Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.
Want to see what other hedge funds are holding CLDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celldex Therapeutics, Inc. (NASDAQ:CLDX).
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2228704/level-four-advisory-services-llc-buys-new-position-in-celldex-therapeutics-inc-cldx.html
Receive News & Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.